$165MVenture, 4 May 2026
Upsized crossover round funds its long-acting TSLP antibody WIN378 through a Phase 2/3 asthma trial and its TSLP/IL-13 bispecific WIN027.
- Amount
- $165M
- Stage
- Venture
- Announced
- 4 May 2026
- Lead
- OrbiMed
- Other investors
- RA Capital Management, Janus Henderson Investors, Sanofi Ventures, Novo Holdings, Harbour BioMed
- Use of funds
- Upsized crossover round funds its long-acting TSLP antibody WIN378 through a Phase 2/3 asthma trial and its TSLP/IL-13 bispecific WIN027.
- Checked
- Announced by the company
- Sources
- Windward Bio announces $165M crossover financing rtwfunds.com
Windward Bio announces $165M crossover financing pulse2.com